David MacNaughtan has served as a Partner and Head of Sagard Healthcare since 2019. David is responsible for overseeing Sagard’s healthcare strategy to invest in approved and commercialized biopharmaceuticals and diagnostics, and medical devices protected by strong intellectual property. He is also a member of the Executive Committee.
Alongside Ali Alagheband and Raja Manchanda, he co-leads the Sagard Healthcare team in their management of the investment process, including origination, due diligence, execution and portfolio management. David is a member of the Sagard Healthcare investment committee. David has known Ali for over 20 years and worked with him at DRI Capital for seven years. He has known Raja for over a decade and worked with him at DRI Capital for two years. He is based in Toronto, Canada
Prior to Sagard, David was a Senior Principal with the CPP Investment Board, leading their intellectual property investment strategy under the direction of Adam Vigna, now Chief Investment Officer at Sagard. David has over 25 years of experience in the biopharmaceutical industry, with roles in operations, business development and finance, including over 20 years of investment experience with royalty-based opportunities.
David holds a B.Sc. and M.Sc. in Applied Science from Queen’s University and an MBA from the University of Toronto, Rotman School of Business.